Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Intravesical Recombinant BCG (Bacillus Calmette Guérin) Followed by Perioperative Chemo-immunotherapy for Patients With Muscle-invasive Bladder Cancer (MIBC). A Multicenter, Single-arm Phase II Trial

NCT04630730 is registered in ClinicalTrials.gov with Swiss Cancer Institute as lead sponsor.

NCT NCT04630730
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04630730 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Intravesical Recombinant BCG (Bacillus Calmette Guérin) Followed by Perioperative Chemo-immunotherapy for Patients With Muscle-invasive Bladder Cancer (MIBC). A Multicenter, Single-arm Phase II Trial
Lead sponsor
Swiss Cancer Institute
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 24, 2022
Completion date
June 30, 2030
Enrollment
46 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer